TB-500 is a synthetic peptide of the naturally occuring healing protein present in about all human and mammalian cells known as Thymosin Beta 4 (TB4). TB 500 is thought to have beneficial effects on wound healing, injury recovery, flexibility, and inflammation. Research indicated the effects of TB 500 are on blood cell and blood vessel development, cellular differentiation, and cell migration. The healing capability is due in large from the peptide’s regulation of actin, a cell building protein essential to healing and wound repair.
TB 500 is produced in the thymus gland and is found in high concentrations in wound fluids. Research demonstrates it has wound healing properties in addition to healing and repair of skin, cornea, and heart.
TB 500 is a naturally occurring peptide also found in high concentrations in blood platelets. TB-500 peptides for research are not growth factors; rather major actin regulating protein peptides. TB 500 plays an important role in protection, regeneration and remodeling of injured and/or damaged tissues. The gene that codes for Thymosin Beta-4 was noted in a study to be one of the first to be stimulated after an incident of injury.
Present in almost all human and animal cells, Thymosin Beta 4 is naturally occurring wound healing peptide. TB 500 , a synthetically made version of TB4 that facilitates comparable healing and recovery by helping building new blood vessels, muscle tissue fibers, blood cells, and facilitating cell migration. For a stressed and injured person, TB 500 can offer an extremely desirable wound healing effects.
No Horsing Around
TB-500 is a synthetic version of Thymosin Beta 4, a protein peptide that occurs naturally in the bodies of both animals and humans. Although TB-500 is available for research purposes, it is commonly used by many veterinarians who conduct clinical trials using TB-500 on horses. It is used to help promote healing from injury and reduce recovery time.
Dr. Allan Goldstein formulated thymosin alpha 1, in order to increase immune cell activity and subsequently thymosin bta 4 or TB-500, in order to accelerate healing and wound repair in animals, such as horses and ?
In racehorses TB 500 has shown significant reductions of inflammation and the inhibition or reduction of adhesions from injury.
The human use of thymosin began in 1974, with the first reported case being a young girl who was injected with thymosin due to a non functioning thymus gland. Since then, an increasing number of athletes and biohackers have been using thymosin all for the very same reasons of repair, reduction of inflammation and to speed up recovery.